This is the text extract for Approval of proposal for parecoxib; Contact: Notifications; Posted: 2012-05-15, browse documents here.

15 May 2012

Approval of proposal to list parecoxib PHARMAC is pleased to announce approval of the proposal to list the hospital medicine parecoxib sodium 40 mg powder for injection (Dynastat) in Part II of Section H of the Pharmaceutical Schedule from 1 June 2012 at a price of $100.00 per pack of 10 injections. Dynastat will also be listed on the national DHB Hospital Preferred Medicine List (PML) from the date of its implementation (currently estimated to be 1 July 2013). This was the subject of a consultation letter dated 29 March 2012. Parecoxib is an injectable COX-2 inhibitor used in DHB hospitals to manage post-operative pain. Effective management of postoperative pain relieves patient suffering and leads to earlier mobilization, shortened hospital stay, and reduced hospital costs. The inclusion of parecoxib in a national PML will mean that it will be available and funded for use by clinicians in all DHB hospitals from the date the PML is implemented. DHB hospitals currently use around 40,000 vials of parecoxib per year. This decision will secure ongoing supply of parecoxib at a lower price than currently paid by DHB hospitals. Feedback received We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 12 March 2012 were considered in their entirety in making a decision on the proposal. All responders supported the proposal. More information If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

A508372

Page 1 of 1